MLchartDataset catalogue

Ch14.18

Term · Oncology and biomedicine · MLC-T-ONC-001633

A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Ch14.18 binds to a substance called GD2, which is found on some types of cancer cells. Ch14.18 may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called dinutuximab, MOAB Ch14.18, monoclonal antibody Ch14.18, and Unituxin.

Table 1. Record
IdentifierMLC-T-ONC-001633
FieldOncology and biomedicine
Synonymsdinutuximab; MOAB Ch14.18; monoclonal antibody Ch14.18; Unituxin
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-001633",
  "term": "Ch14.18",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Ch14.18 binds to a substance called GD2, which is found on some types of cancer cells. Ch14.18 may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called dinutuximab, MOAB Ch14.18, monoclonal antibody Ch14.18, and Unituxin.",
  "synonyms": [
    "dinutuximab",
    "MOAB Ch14.18",
    "monoclonal antibody Ch14.18",
    "Unituxin"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/ch14-18/"
}

Record 4,664 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.